AstraZeneca, Eolas in $145m deal for anti-smoking drug
This article was originally published in Scrip
Executive Summary
Carlsbad, California-based private biotechnology firm Eolas Therapeutics could earn up to $145m in upfront, clinical and regulatory milestone fees plus royalties from AstraZeneca under an agreement to develop an orexin-1 receptor antagonist (EORA) for smoking cessation and other indications.